Anti-CD33 Neutralizing Antibody (V3S-0622-YC4319) (CAT#: V3S-0622-YC4319)

Figure 1 Anti-CD33 Monoclonal Antibody (V3S-0622-YC4319) Fab Fragment in DB

Dot Blot analysis of V3S-0622-YC4319 Fab fragment was performed by coating with human CD33 protein (His tag).

V3S-0622-YC4319 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-His tag as a secondary antibody (1: 2000)

Figure 2 Anti-CD33 Monoclonal Antibody (V3S-0622-YC4319) Fab Fragment in WB

Western blot analysis of V3S-0622-YC4319 Fab fragment was performed by loading human CD33 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4319 and HRP goat anti-His tag as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.5 μg)
Lane 2: Reduced antigen (0.8 μg)
Lane 3: Reduced antigen (1.0 μg)

Figure 1 Anti-CD33 Monoclonal Antibody (V3S-0622-YC4319) in SEC-HPLC

The purity of V3S-0622-YC4319 was greater than 90% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.3
Detection: UV 280 nm
Injection: 25 µl

Figure 2 Anti-CD33 Monoclonal Antibody (V3S-0622-YC4319) in WB

Western blot analysis of V3S-0622-YC4319 was performed by loading Recombinant Human CD33 Protein onto a 12% Tris-HCl polyacrylamide gel. The secondary antibody: Goat Anti-Human IgG-HRP.
Lane 1: Non-Reducing Antigen (0.5 μg)
Lane 2: Reducing Antigen (0.5 μg)

Figure 3 Anti-CD33 Monoclonal Antibody (V3S-0622-YC4319) in ELISA

ELISA analysis of V3S-0622-YC4319 was performed by coating with Recombinant Human CD33 Protein. Then blocked with BSA, and incubated with Anti-Human CD33 Antibody (V3S-0622-YC4319). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.